New hope for advanced kidney cancer when first treatments stop working
NCT ID NCT03945773
Summary
This study tested the drug cabozantinib as a second treatment for people with advanced kidney cancer that had spread and worsened after their first treatment with immunotherapy. The goal was to see if the drug could shrink tumors and control the disease. It involved 127 adults and measured how well and for how long the treatment worked, along with its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
CHRU Besançon
Besançon, 25000, France
-
CHU Strasbourg
Strasbourg, 67091, France
-
CHU de Nîmes - Institut de Cancérologie du Gard
Nîmes, 30029, France
-
Caritas Krankenhaus St.Josef Klinik für Urologie
Regensburg, D-93053, Germany
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Universitaire Vaudois
Lausanne, 1011, Switzerland
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hospital Lucus Augusti
Lugo, 27003, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital de La Santa Creu i Sant Pau
Barcelona, 08041, Spain
-
Institut Claudius Régaud
Toulouse, 31059, France
-
Institut Mutualiste Montsouris
Paris, 75014, France
-
Institut Paoli Calmettes
Marseille, 13009, France
-
Institut de Cancérologie de Lorraine
Nancy, 54511, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, 44800, France
-
Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
-
Klinikum Der Friedrich-Schiller-Universitaet Jena
Jena, D-07747, Germany
-
Leiden University Medical Center
Leiden, 2300-RC, Netherlands
-
M.D. Anderson Center Madrid
Madrid, 28033, Spain
-
Maxima Medisch Centrum
Eindhoven, 5604 DB, Netherlands
-
Medizinische Hochschule Hannover
Hanover, D-30625, Germany
-
Mount Vernon Hospital
Northwood, HA6 2RN, United Kingdom
-
Otto-von-Guericke-Universität University hospital Magdeburg
Magdeburg, D-39120, Germany
-
Royal Cornwall Hospital (RCH) - Sunrise Centre
Truro, TR1 3LJ, United Kingdom
-
SALK - Salzburger Landesklinik
Salzburg, A-5020, Austria
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The Netherlands Cancer Institute - Oncology
Amsterdam, 1066 CX, Netherlands
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
-
University Cancer Center Hamburg Eppendorf
Hamburg, d-20246, Germany
-
University Hospital Carl Gustav Carus Dresden
Dresden, D-1307, Germany
-
University Hospital Tuebingen
Tübingen, D-72076, Germany
-
University, Hospital Münster
Münster, D-48149, Germany
-
Universitätsklinikum Essen
Essen, D-45147, Germany
-
Universitätsklinikum Schleswig-Holstein
Lübeck, D-23538, Germany
-
Universitätsmedzin Charité
Berlin, D-10117, Germany
-
Universitätsspital Bern, Inselspital
Bern, 3010, Switzerland
-
Western General Hospital - Edinburgh Cancer Centre
Edinburgh, EH4 2XU, United Kingdom
Conditions
Explore the condition pages connected to this study.